Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / XGN - Exagen Inc. to Participate in December Investor Conferences


XGN - Exagen Inc. to Participate in December Investor Conferences

SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor conferences:

  • Piper Sandler 32 nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020
    A recorded company presentation will be available via the Piper Sandler conference site from November 23 to December 3, and on the Exagen website at: https://investors.exagen.com/events
  • Evercore ISI 3 rd Annual HealthCONx Conference, December 1-3, 2020
    Exagen President and CEO Ron Rocca will participate in a Fireside Chat on Wednesday, December 2, 2020, at 10:30 am EST. A link to the live webcast of the Fireside Chat will be posted to the Exagen website at: https://investors.exagen.com/events

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients.  For more information, please visit www.Exagen.com .

Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514


Stock Information

Company Name: Exagen Inc.
Stock Symbol: XGN
Market: NYSE
Website: exagen.com

Menu

XGN XGN Quote XGN Short XGN News XGN Articles XGN Message Board
Get XGN Alerts

News, Short Squeeze, Breakout and More Instantly...